A concurrent clinical trial investigated the impact of the ACLY inhibitor ETC-1002 (bempedoic acid) on patients with atherosclerotic cardiovascular disease, heterozygous familial hypercholesterolemia, or both (Ference et al., 2019). This evidence concerns the gene ACLY and familial hypercholesterolemia.